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AbstrACt
Objectives to compare the effects of rituximab versus 
placebo on salivary gland ultrasound (sGUs) in primary 
sjögren’s syndrome (pss) in a multicentre, multiobserver 
phase iii trial substudy.
Methods subjects consenting to sGUs were 
randomised to rituximab or placebo given at weeks 0, 2, 
24 and 26, and scanned at baseline and weeks 16 and 
48. sonographers completed a 0–11 total ultrasound 
score (tUs) comprising domains of echogenicity, 
homogeneity, glandular definition, glands involved and 
hypoechoic foci size. Baseline-adjusted tUs values were 
analysed over time, modelling change from baseline 
at each time point. For each tUs domain, we fitted a 
repeated-measures logistic regression model to model 
the odds of a response in the rituximab arm (≥1-point 
improvement) as a function of the baseline score, age 
category, disease duration and time point.
results 52 patients (n=26 rituximab and n=26 placebo) 
from nine centres completed baseline and one or more 
follow-up visits. estimated between-group differences 
(rituximab-placebo) in baseline-adjusted tUs were −1.2 
(95% Ci −2.1 to −0.3; p=0.0099) and −1.2 (95% Ci 
−2.0 to −0.5; p=0.0023) at weeks 16 and 48. Glandular 
definition improved in the rituximab arm with an or of 
6.8 (95% Ci 1.1 to 43.0; p=0.043) at week 16 and 10.3 
(95% Ci 1.0 to 105.9; p=0.050) at week 48.
Conclusions We demonstrated statistically significant 
improvement in tUs after rituximab compared with 
placebo. this encourages further research into both B 
cell depletion therapies in pss and sGUs as an imaging 
biomarker.
trial registration number 65360827, 2010-021430-
64; results.
IntrOduCtIOn
Primary Sjögren’s syndrome (PSS) is characterised 
by focal lymphocytic infiltration of exocrine glands 
leading to profound dryness. It is often accompa-
nied by systemic manifestations and high levels of 
fatigue. B cells are considered to have a central 
role in pathogenesis,1 and two small randomised 
controlled trials (RCTs) of the anti-CD20 B-cell-de-
pleting agent rituximab suggested benefits in 
PSS.2 3 Rituximab may also have effects on interleu-
kin-17-producing mast cells and on a CD20-posi-
tive T cell subset.4 5 Despite this, French (TEARS) 
and British (TRACTISS) phase III RCTs failed to 
demonstrate an effect on primary endpoints based 
on patient-reported visual analogue scales (VAS).6 7 
Potential explanations for these disappointing find-
ings include the lack of patient stratification, insuf-
ficient tissue depletion of B cells and the choice and 
timing of primary outcome.
The requirement for new and validated outcome 
measures for PSS led to the development of the 
European Sjögren’s Syndrome Patient Reported 
Index (ESSPRI) and a physician-assessed systemic 
disease activity index (European League Against 
Rheumatism Sjögren’s Syndrome Disease Activity 
Index (ESSDAI)).8 These are a welcome advance, 
but certain limitations suggest that additional objec-
tive outcome measures/biomarkers would be desir-
able. Use of the ESSDAI, for example, requires a 
minimum threshold for trial entry that excludes 
a large proportion of patients. Other outcome 
measures include salivary flow rates, although 
these are subject to issues of standardisation and 
diurnal variation,9 and histological examination of 
salivary gland biopsies, which may provide mecha-
nistic information but is invasive.10 11 Salivary gland 
ultrasound (SGUS) is readily available, non-invasive 
and shows reasonable sensitivity and good speci-
ficity for the diagnosis of PSS.12–14 In PSS, glandular 
echogenicity is altered and there is loss of homoge-
neity due to the presence of multiple hypoechoic 
or anechoic areas, as well as hyperechoic bands. 
Loss of definition of the glandular border may 
also be observed. A single-site substudy of SGUS in 
TEARS showed that a greater number of patients 
had improvement in parotid gland echostructure at 
24 weeks after rituximab compared with placebo.15 
to cite: Fisher BA, 
everett CC, rout J, 
et al. Ann Rheum Dis 
2018;77:412–416.
Handling editor tore K Kvien
 ► Additional material is 
published online only. to view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
annrheumdis- 2017- 212268).
For numbered affiliations see 
end of article.
Correspondence to
Dr Benjamin A Fisher, 
rheumatology research Group, 
institute of inflammation 
and Ageing, University of 
Birmingham, Birmingham B15 
2tt, UK;  b. fisher@ bham. ac. uk
An abstract of this work was 
previously presented at the 
2017 American College of 
rheumatology Annual Congress.
received 21 August 2017
revised 1 December 2017
Accepted 1 December 2017
published online First 
23 December 2017
413Fisher BA, et al. Ann Rheum Dis 2018;77:412–416. doi:10.1136/annrheumdis-2017-212268
Clinical and epidemiological research
Echostructure was assessed on a 0–4 scale that graded the pres-
ence of hypoechoic areas as well as hyperechoic bands. SGUS 
is, however, an operator-dependent technique, and its utility in 
a multicentre study is uncertain. Here we report the results of a 
multiobserver, multicentre SGUS substudy of TRACTISS over a 
longer therapeutic timeframe.
MetHOds
The TRACTISS study has been previously described.6 Briefly, 
133 patients with PSS were randomised 1:1 to 1000 mg ritux-
imab or placebo given at weeks 0, 2, 24 and 26. Patients and 
clinicians were blind to the randomised allocation. The primary 
outcome (30% reduction in either oral dryness or fatigue VAS) 
was assessed at week 48. Methylprednisolone 100 mg was given 
prior to each infusion of rituximab or placebo. Subjects could 
consent to an optional SGUS substudy, with assessments at base-
line and weeks 16 and 48. The prespecified substudy primary 
outcome was total ultrasound score (TUS, range 0–11; table 1). 
Normal salivary gland echogenicity was defined through simi-
larity with the thyroid. The consistency domain scored the extent 
of heterogeneity introduced by the presence of hypoechoic areas. 
The definition domain addressed whether the posterior glan-
dular border was normally visible or else incompletely defined or 
not possible to define. The hypoechoic foci size domain catego-
rised the size of the glandular hypoechoic lesions that were most 
typical for that patient. Imaging followed a standard sequence 
including both transverse and longitudinal views of both parotid 
and submandibular glands, with data recorded by the sonogra-
pher on a study proforma. Additional information was collected 
for each of the four major salivary glands on vascularity of the 
gland parenchyma assessed by power Doppler, gland echoge-
nicity (normal, heterogenous or hypoechoic), gland margins 
(well or ill-defined), approximate hypoechoic foci number (0, 
1–5, 5–9 and >10), hypoechoic foci size (<3, 3–7 and >8 mm), 
as well as domains capturing lymph node abnormalities.
ESSPRI score was calculated as the mean of 0–10 scales for 
dryness, fatigue and limb pain. The ESSDAI score was scored 
by the local investigator. Unstimulated whole salivary flow was 
collected over 15 min, and stimulated whole salivary flow over 
10 min following application of citric acid with a cotton swab to 
the lateral borders of the tongue every 60 s.
TUS was modelled using mixed effects linear regression, 
including baseline score, patient age, disease duration and time 
point. Odds of domain improvement were modelled by repeat-
ed-measures logistic regression, including baseline score, age, 
disease duration and time point. Descriptive summary statis-
tics, scatterplots and boxplots were produced to explore and 
summarise the data.
results
In total, 66 patients (49.6%) from the total study population 
consented to SGUS, and 52 (39.1%; n=26 rituximab and 
n=26 placebo) patients from nine centres completed the baseline 
and at least one follow-up visit. Of these 52 patients, 43 (83%) 
completed all three visits. There were no apparent differences 
in relevant characteristics between those consenting and not 
consenting to the substudy (online supplementary table S1). The 
two arms of the substudy were also similar (table 2), although 
TUS in the rituximab arm was on average one point greater.
Figure 1 illustrates the baseline-adjusted values of TUS over 
time, modelling the change from baseline at each time point. 
Estimated baseline-adjusted TUS at week 16 was 6.2 (95% CI 
5.4 to 7.0) for placebo and 5.0 (95% CI 4.4 to 5.6) for ritux-
imab, and at week 48, 6.1 (95% CI 5.5 to 6.6) and 4.8 (95% CI 
4.2 to 5.4), respectively. Estimated between-group differences 
(rituximab-placebo) in baseline-adjusted TUS were −1.2 (95% 
CI −2.1 to −0.3; P=0.0099) and −1.2 (95% CI −2.0 to –0.5; 
P=0.0023) at weeks 16 and 48, respectively.
For each TUS domain, we fitted a repeated-measures logistic 
regression to model the odds of a response in the rituximab arm 
(defined as ≥1-point improvement) as a function of the baseline 
score, age category, disease duration and time point. Glandular 
definition was the only domain to show statistically significant 
improvement with an OR of 6.8 (95% CI 1.1 to 43.0; P=0.043) 
at week 16 and 10.3 (95% CI 1.0 to 105.9; P=0.050) at week 48 
(online supplementary table S2). No difference between ritux-
imab and placebo was observed in any of the additional explor-
atory ultrasound parameters collected, with the exception of 
gland margin scores which showed deterioration in the placebo 
group (mean sum of scores over all glands increasing from 1.8 
(SD 1.95) at baseline to 2.4 (SD 1.89) at 48 weeks compared 
with 2.3 (SD 1.83) to 2.4 (SD 1.97) in the rituximab group).
Improvement of ≥1 point in TUS, compared with no improve-
ment or worsening, was not associated with improvement in 
unstimulated or stimulated salivary flow rates, ESSPRI score or 
dryness domain VAS at weeks 16 or 48, in the whole popula-
tion or when analysing the rituximab arm alone. No associa-
tions were observed with ≥1-point improvement in either the 
glandular definition or hypoechoic foci size domains. TUS did 
not correlate with total ESSDAI score, the ESSDAI glandular 
domain or salivary flow rates at any time point, either in the 
whole population or the rituximab arm. Baseline TUS was not 
correlated with improvement in salivary flow rates, ESSPRI or 
oral dryness VAS at either week 16 or 48 in the rituximab arm 
(data not shown).
dIsCussIOn
We demonstrated a statistically significant improvement in TUS 
after rituximab compared with placebo. While this observation 
is similar to that in the TEARS substudy, there are a number of 
key differences. First, in TRACTISS rituximab was given at base-
line and then again at 6 months, with a longer follow-up to 48 
weeks. Second, the TRACTISS substudy was larger, multicentre 
and multiobserver. The ability of ultrasound to detect changes 
table 1 Domains of the total ultrasound score 
domain description score
Echogenicity Normal 0
Hypoechoic 1
Consistency Normal 0
Mild heterogeneity 1
Evident honeycombed 2
Gross multifocal 3
Definition Normal 0
Moderately defined 1
Ill-defined 2
Glands involved None 0
Parotids or submandibular glands 1
All glands 2
Hypoechoic foci size None 0
Small 2–5 mm 1
Large 5–8 mm non-vascular 2
Over 8 mm ± vascular 3
Total 0–11
414 Fisher BA, et al. Ann Rheum Dis 2018;77:412–416. doi:10.1136/annrheumdis-2017-212268
Clinical and epidemiological research
in this setting is important in encouraging further development 
of this tool. Third, TRACTISS used a composite SGUS score. 
Fourth and related to the last point, the number and size of 
hypoechogenic foci showed no change in TRACTISS, in contrast 
to the TEARS study.
The pathological correlate of the hypoechoic areas observed 
on ultrasound in PSS is uncertain. In TEARS, there was a 
correlation between histological focus score and SGUS score, 
suggesting that hypoechoic areas represent areas of inflamma-
tory cell infiltrate.16 Furthermore, both high baseline SGUS 
score and high numbers of infiltrating B cells were predictive of 
non-response.17 18 However, opposite findings on B cell infiltra-
tion and rituximab responsiveness have been reported by Delli 
et al,19 and in a cohort of patients with suspected PSS there was 
only a modest agreement between the same SGUS score and 
biopsy.13 Therefore, it remains possible that the highest grades of 
hypoechoic lesions might reflect damage as well as inflammation 
in a subset of patients, explaining why we observed no change in 
their size or number.
Our results suggest that glandular definition was an important 
domain driving change in TUS. While there is a pragmatic attrac-
tiveness in simplified scores focusing on hypoechoic areas for 
diagnosis,20 our data encourage the collection of a wider range 
of features/domains in clinical trials as there is yet much to learn 
about the responsiveness of US to effective treatments in PSS.
The clinical significance of our findings is uncertain. TRAC-
TISS did not meet its primary endpoint,6 and no associa-
tion between TUS improvement and salivary flow was found. 
We also found no apparent inverse association between sali-
vary flow rates and TUS at baseline, in contrast to previous 
cross-sectional studies, which may reflect our small sample size 
given that previously reported correlations were only fair to 
moderate.21 22 Furthermore, the improvement in the glandular 
definition domain was only of marginal statistical significance. 
table 2 Selected baseline characteristics of subjects with both baseline and follow-up data in salivary gland ultrasound substudy
Placebo
(n=26)
rituximab
(n=26)
All
(n=52)
Age (years) 57.4 (11.1) 56.7 (10.92) 57.1 (10.91)
Years since diagnosis 6.6 (5.67) 5.38 (4.82) 6.0 (5.25)
≥10 years since diagnosis, n (%) 6 (23.1) 4 (15.4) 10 (19.2)
Female sex, n (%) 23 (88.5) 25 (96.2) 48 (92.3)
Current medications (prior to randomisation)
  Pilocarpine, n (%) 1 (3.8) 4 (15.4) 5 (9.6)
  Hydroxychloroquine, n (%) 13 (50.0) 15 (57.7) 28 (53.8)
  Corticosteroids, n (%) 6 (23.1) 2 (7.7) 8 (15.4)
  NSAIDS: n (%) 7 (26.9) 5 (19.2) 12 (23.1)
Unstimulated salivary flow (mL/15 min) 1.4 (2.34) 0.8 (0.71) 1.1 (1.72)
Stimulated salivary flow (mL/10 min) 3.8 (4.08) 3.7 (5.51) 3.7 (4.82)
IgG (g/L) 17.2 (7.67) 17.8 (6.02) 17.5 (6.82)
IgA (g/L) 3.7 (2.87) 3.0 (1.0) 3.3 (2.14)
IgM (g/L) 1.2 (0.64) 1.4 (0.65) 1.28 (0.64)
Anti-Ro autoantibody positive, n (%) 26 (100) 25 (96.2) 51 (98.1)
Reduced C4, n (%) 4 (15.4) 4 (15.4) 8 (15.4)
Visual analogue scales (average over last two weeks, mm; 100=severe, except global)
  Fatigue 74.5 (13.46) 67.0 (18.22) 70.8 (16.30)
  Oral dryness 75.6 (15.13) 73.8 (13.30) 74.7 (14.14)
  Ocular dryness 64.7 (23.25) 65.7 (19.25) 65.2 (21.09)
  Overall dryness 73.4 (15.64) 71.3 (13.17) 72.4 (14.36)
  Joint pain 56.4 (28.40) 47.2 (27.21) 51.8 (27.93)
  Global assessment (100=PSS very active) 73.4 (14.08) 62.2 (18.90) 67.8 (17.45)
ESSPRI (10=maximal symptom severity) 6.7 (1.63) 6.4 (1.64) 6.6 (1.64)
ESSDAI (123=maximal disease activity) 6.8 (3.82) 5.1 (4.55) 6.0 (4.24)
ESSDAI glandular domain, n (%)
  No activity 17 (65.4) 22 (84.6) 39 (75.0)
  Low activity 8 (30.8) 3 (11.5) 11 (21.2)
  Moderate activity 1 (3.8) 1 (3.8) 2 (3.8)
TUS 5.02 (3.06) 6.5 (2.04) 5.9 (2.65)
TUS domains
  Echogenicity 0.5 (0.51) 0.8 (0.43) 0.7 (0.48)
  Consistency 1.3 (1.00) 1.5 (0.91) 1.4 (0.95)
  Definition 0.8 (0.83) 1.3 (0.74) 1.0 (0.82)
  Glands involved 1.5 (0.81) 1.9 (0.43) 1.7 (0.67)
  Hypoechoic foci size 1.0 (0.68) 1.1 (0.48) 1.1 (0.58)
Values are mean and SD unless otherwise stated.
ESSDAI, European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index; ESSPRI, European Sjögren’s Syndrome Patient Reported Index; NSAID, non-steroidal 
anti-inflammatory drugs; PSS, primary Sjögren’s syndrome; TUS, total ultrasound score.
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We used a novel composite score, designed to be comprehensive 
but also pragmatic, but which predated the EULAR pSS working 
group reference atlas.23 Other limitations include the small 
number of subjects and the multiplicity of statistical compari-
sons, for which we did not adjust our nominal significance levels. 
Although the sonographers in this study were experienced in 
SGUS, ultrasound machines were not standardised between 
centres, and some domains, especially the definition domain, can 
be difficult to assess. Intraobserver and interobserver reliability 
was not studied and could have impacted our findings; further 
standardisation of SGUS in PSS is urgently required. Arguably, 
however, the ability to distinguish treatment arms despite such 
standardisation may increase the relevance of our findings.
There is good reason to believe that rituximab monotherapy 
may stimulate new autoimmune B cells through elevation in 
BLyS levels24 and may be inefficient at depleting tissue B cells.25 
The fact that we observed a difference in TUS between study 
arms despite these limitations encourages further research on B 
cell depletion therapy in PSS, including use of combination ther-
apies,26 and on SGUS as an imaging biomarker.
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